• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clinical global impressions in Alzheimer's clinical trials.

作者信息

Schneider L S, Olin J T

机构信息

Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, USA.

出版信息

Int Psychogeriatr. 1996 Summer;8(2):277-88; discussion 288-90. doi: 10.1017/s1041610296002645.

DOI:10.1017/s1041610296002645
PMID:8994897
Abstract

This article reviews the history of Clinical Global Impressions of Change (CGIC) instruments, their use and limitations in clinical trials of Alzheimer's disease, and the development of the National Institute on Aging's Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Scale (ADCS-CGIC). Originally, CGICs were simple and unstructured instruments that asked a clinician to rate change over the duration of a clinical trial. The method, however, failed to consistently detect treatment effects, leading to the development of more structured and subsequently validated approaches, such as the Clinician Interview-Based Impression Scale (CIBI) and the ADCS-CGIC. Both are currently used in clinical trials. The implications and importance of choosing an appropriate global rating are discussed.

摘要

相似文献

1
Clinical global impressions in Alzheimer's clinical trials.
Int Psychogeriatr. 1996 Summer;8(2):277-88; discussion 288-90. doi: 10.1017/s1041610296002645.
2
ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.阿尔茨海默病协作研究预防工具项目:阿尔茨海默病协作研究临床医生总体变化印象量表(ADCS-CGIC),自评版和研究伙伴评定版。
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S124-38. doi: 10.1097/01.wad.0000213878.47924.44.
3
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.阿尔茨海默病协作研究-临床总体变化印象的效度与信度。阿尔茨海默病协作研究。
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32. doi: 10.1097/00002093-199700112-00004.
4
The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.基于临床医生访谈的印象(CIBI):阿尔茨海默病中临床医生的整体变化评定量表
Neurology. 1994 Dec;44(12):2315-21. doi: 10.1212/wnl.44.12.2315.
5
Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.重酒石酸卡巴拉汀透皮贴剂和胶囊对阿尔茨海默病临床总体印象变化的影响:回顾性分析。
Dement Geriatr Cogn Disord. 2010;29(5):406-12. doi: 10.1159/000296073. Epub 2010 May 21.
6
Clinical evaluation of global change in Alzheimer's disease: identifying consensus.
J Geriatr Psychiatry Neurol. 1996 Oct;9(4):176-80. doi: 10.1177/089198879600900404.
7
Global measures: utility in defining and measuring treatment response in dementia.整体测量指标:在痴呆症治疗反应的定义和测量中的效用
Int Psychogeriatr. 2007 Jun;19(3):421-56. doi: 10.1017/S1041610207005261.
8
The Alzheimer's Disease Assessment Scale.阿尔茨海默病评估量表
Int Psychogeriatr. 1996 Summer;8(2):195-203. doi: 10.1017/s1041610296002578.
9
Galantamine for Alzheimer's disease.加兰他敏用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2001(4):CD001747. doi: 10.1002/14651858.CD001747.
10
Galantamine for Alzheimer's disease.加兰他敏用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2001(1):CD001747. doi: 10.1002/14651858.CD001747.

引用本文的文献

1
Electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD): A modified study protocol.电抽搐治疗用于痴呆严重激越的急性期管理(ECT-AD):改良研究方案。
PLoS One. 2024 Jun 28;19(6):e0303894. doi: 10.1371/journal.pone.0303894. eCollection 2024.
2
Feedback System Analysis of a Multicomponent Intervention on Dyads of Home-Dwelling Persons With Dementia and Their Caregivers: Results From the LIVE@Home.Path Trial.对居家痴呆患者及其照护者二元组进行多成分干预的反馈系统分析:来自LIVE@Home.Path试验的结果
Innov Aging. 2024 Feb 23;8(3):igae020. doi: 10.1093/geroni/igae020. eCollection 2024.
3
Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion.
动态客观运动测量对左旋多巴/卡比多巴肠凝胶输注结果的预测价值。
J Pers Med. 2022 Jan 2;12(1):27. doi: 10.3390/jpm12010027.
4
Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems.关节内骨关节炎药物递送系统临床转化的最新进展
Adv Ther (Weinh). 2021 Jan;4(1). doi: 10.1002/adtp.202000088. Epub 2020 Sep 28.
5
Development of an adapted Clinical Global Impression scale for use in Angelman syndrome.用于安格曼综合征的适应性临床总体印象量表的制定。
J Neurodev Disord. 2021 Jan 4;13(1):3. doi: 10.1186/s11689-020-09349-8.
6
Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial.复方中药赛络通治疗血管性痴呆的疗效与安全性:一项随机临床试验
Alzheimers Dement (N Y). 2018 Mar 22;4:108-117. doi: 10.1016/j.trci.2018.02.004. eCollection 2018.
7
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.玛伐格卢兰特治疗脆性X综合征青少年:一项双盲治疗研究及后续开放标签长期扩展研究的临床总体印象改善源数据分析
J Neurodev Disord. 2016;8:1. doi: 10.1186/s11689-015-9134-5. Epub 2015 Dec 15.
8
Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.痴呆前阿尔茨海默病试验的认知/临床终点
J Prev Alzheimers Dis. 2015;2(2):82-84. doi: 10.14283/jpad.2015.62.
9
The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.BEHAVE-AD评估系统:一种观点、对新发现的评论及历史回顾。
Dement Geriatr Cogn Disord. 2014;38(1-2):89-146. doi: 10.1159/000357839. Epub 2014 Apr 7.
10
Predictors of institutionalization of dementia patients in mild and moderate stages: a 4-year prospective analysis.轻度和中度痴呆患者机构化的预测因素:一项为期4年的前瞻性分析。
Dement Geriatr Cogn Dis Extra. 2013 Nov 1;3(1):426-45. doi: 10.1159/000355079. eCollection 2013.